These results expand our understanding of the mechanism and specificity of TDZD RGS inhibitors and support the potential for therapeutic targeting of RGS proteins in Parkinson's disease and other neural disorders.
Introduction: G protein-coupled receptors (GPCRs) remain key drug targets for therapeutic use (1) (2) (3) . The recent crystal structures of numerous GPCRs have improved the ability to develop subtype-selective ligands (4, 5) . Also, allosteric modulators of GPCRs have provided new degrees of control of signaling with the potential for more refined therapeutic agents (2, 6) . In some cases, however, a single GPCR may mediate both desired and unwanted actions. This is especially true for agonists (e.g. clondine and adenosine) active in the central nervous system (CNS) where side effects are major limitations to use. It would be highly advantageous to have a mechanism to improve the selectivity of existing GPCR ligands. The downstream actions of GPCRs are modulated by the family of Regulator of G protein Signaling proteins (RGS proteins). Many of the 20 members of this family are abundantly expressed in the brain (7) (8) (9) (10) (11) (12) (13) . Consequently, they have been proposed as intriguing CNS drug targets (7) (8) (9) (10) (11) (12) (13) . RGS proteins act intracellularly by speeding the deactivation of Gα i and Gα q family G proteins. Inhibition of RGS proteins would thus be expected to potentiate the actions of GPCR agonists.
Furthermore, the differential tissue distribution of RGS proteins could provide a novel way to selectively enhance GPCR agonist action in a tissue-specific or neuron-subtype specific manner.
RGS4, in particular, assembles in a complex with A1 adenosine receptors and has been proposed to suppress the anticonvulsant action of adenosine (14) . Suppression of RGS4 also mediates long-term depression by dopamine through D2 receptors in medium spiny neurons (15) and RGS4 knockout mice have reduced impairment in 6-OHDA mouse models (15) . Furthermore, loss of RGS4 appears to suppress abnormal involuntary movements in mice which represents a model for DOPA-induced dyskinesias (16) . According to the recent model (15) , a key action of dopamine is to suppress RGS4 function. Thus, direct, chemical inhibition of the hyperactive RGS4 would eliminate the need for dopamine and could provide a novel dopamine-independent approach to Parkinson's disease. Consequently, therapeutic targeting of RGS4 could be of great interest.
It has been challenging to effectively disrupt RGS4/Gα and other protein-protein interactions, especially in the CNS, but progress is being made (17) (18) (19) . Indeed, the emerging consensus in the field is that effective inhibitors of protein-protein interactions (iPPIs) may not meet the "standard" pharmaceutical criteria for drug-like molecules (20, 21) . In spite of this, numerous compounds with MW > 500 (20) (21) (22) and several covalent protein modifiers (23, 24) are now in clinical trials. We recently described a series of nanomolar-potency TDZD inhibitors of RGS proteins (25, 26) that can disrupt RGS4 binding to Gα subunits in HEK-293 cells. As is seen for some other potent iPPIs, they covalently modify cysteine residues in RGS proteins (25) but, surprisingly, they have high specificity for RGS4 vs. other cysteine-dependent proteins such as some kinases and cysteine proteases.
In this study, we assess the specificity of TDZD RGS4 inhibitors and demonstrate cellular activity on RGS4 actions on Gα q -mediated cellular Ca ++ signaling and delta-opioid regulation of adenylyl cyclase. Furthermore, CCG-203769 shows in vivo activity on muscarinic control of heart rate as well as in reversing raclopride-induced Parkinson's-like effects. These results represent the first demonstration of in vivo effects of TDZD RGS4 inhibitors and implicate a potential role in Parkinson's disease and other neuropsychiatric disorders.
Results and Discussion:
Identifying selective small molecule inhibitors of protein-protein interactions with activity in the central nervous system remains a key challenge to the expansion of the current therapeutic repertoire beyond receptors, transporters, and kinases. Our previously described RGS4 inhibitor CCG-203769 blocks the RGS4-Gα o protein-protein interaction in vitro with an IC 50 value of 17 nM in the Flow Cytometry Protein Interaction Assay (FCPIA, Figure 1A ). More importantly, it also displays dramatic selectivity for RGS4 over other RGS proteins (Table 1) .
The closely related RGS8 is very weakly inhibited (IC 50 >60 µM) providing >4500-fold selectivity for RGS4 ( Figure 1A , Table 1 ). This difference is greater than that seen for our earlier TDZD inhibitor, CCG-50014, which was only ~350-fold selective for RGS4 over RGS8 (25, 26) . CCG-203769 inhibits RGS19 with an IC 50 of 140 nM (8-fold selective for RGS4) and 6 µM for RGS16 (350-fold). As with previously reported RGS4 inhibitors, CCG-203769 does not inhibit RGS7, which lacks cysteines in the RGS domain (Table 1 ).
In addition to inhibiting RGS4/Gα binding, CCG-203769 also blocks the GTPase accelerating protein (GAP) activity of RGS4. In single-turnover and steady-state GTPase experiments with Gα o and Gα i1 , the rate of GTP hydrolysis is strongly stimulated by RGS4 and this effect is inhibited by CCG-203769 with an IC 50 < 1 µM ( Figure. 1B, C). As previously shown for the related TDZD compound CCG-50014 (25) , our new compound is irreversible in nonreducing buffers ( Figure 1D ). This, as well as the complete lack of effect on RGS7, is consistent with CCG-203769 having the same thiol-modification mechanism as CCG-50014 (25) .
Beyond RGS protein specificity, CCG-203769 is highly selective for RGS4 vs other thiol-dependent proteins. To assess effects on a protein with a catalytic cysteine residue, we 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 tested CCG-203769 for inhibition of the cysteine protease papain. The general thiol-reactive reagent iodoacetamide strongly inhibited papain-mediated hydrolysis of the fluorescent casein substrate at 30 µM. CCG-203769 at the same concentration had no effect on the protease activity of papain ( Figure 1E ). Related TDZD compounds are inhibitors of glycogen synthase kinase 3β (27) (28) (29) . Indeed, they are currently being evaluated in clinical trials for depression and Alzheimer's disease based on this proposed mechanism. Using a radiometric assay, we show that CCG-203769 inhibits GSK-3β with an IC 50 value of 5 µM ( Figure 1F ). This represents 300-fold selectivity of our compound for RGS4 vs. GSK-3β.
The nanomolar potency on RGS4 in vitro translates to respectable cellular activity. We first examined the RGS4/Gα o interaction in HEK293 cells. RGS4 is typically present in the cytoplasm but translocates to the membrane when co-expressed with a Gα subunit as demonstrated previously (25) . Similar to prior results with CCG-50014 (25) , CCG-203769 also carbachol. This is similar to previously observed, though more dramatic, effects of CCG-50014 to disrupt Ca ++ handling in HEK cells (26) .
We used SH-SY-5Y neuroblastoma cells to study endogenously expressed RGS and opioid receptors. Wang et al (30) had previously shown that RGS4 specifically regulates deltaopioid receptor (DOP) signaling while having little to no effect on mu-opioid receptor (MOP)
signaling. CCG-50014 significantly potentiates SNC-80 effects on cAMP accumulation through DOP ( Figure 3C ). Consistent with the previously determined specificity of RGS4, there was no significant effect of the compound on MOP-regulated cAMP levels though a trend toward potentiation of morphine activity was observed. Although the TDZD inhibitors have cellular activity, specificity is always a key question regarding compounds with a covalent mechanism of action. As noted above, CCG-203769 has low potency against GSK-3β as well as producing no inhibition of the activity of the thiolprotease papain at 30 µM. We also assessed off-target effects through broad activity profiling at the NIMH PDSP program (University of North Carolina, Chapel Hill) (31) . The compound showed no activity at 10 µM against a series of receptors, transporters, etc (Table 2 and S1).
CCG-203769 had modest activity to inhibit ligand binding in membrane preparations for a small subset of the tested systems (α2 adrenergic, D3 dopamine, and opioid receptors). Using the Glowsensor assay (32, 33) for inhibition of cAMP in cells by these Gα i/o -coupled receptors, the TDZD compounds showed no agonist or antagonist activity at concentrations up to 10 µM in cells (Table 2 ). (34) . To determine whether this genetic disruption of RGS4 function could be replicated pharmacologically, we tested CCG-203769 for effects on carbachol-mediated bradycardia in conscious, unrestrained rats. Carbachol (0.1 mg/kg, IP)
produces a modest decrease in heart rate ( Figure 4 ) compared to a saline vehicle control.
CCG-203769 (10 mg/kg, IV) had no significant effect upon heart rate when given alone ( Figure   4 ). However, CCG-203769, administered immediately prior to carbachol, significantly potentiated the bradycardic effect ( Figure 4 , p<0.05, 2-way ANOVA).
Given the functional role of RGS4 in Parkinson's disease models (15) , we tested CCG-203769 in a pharmacologic model of D2 antagonist-induced bradykinesia. Raclopride administration in rats causes increased hang time in the bar test ( Figure 5A ) which was rapidly reversed by doses of CCG-203769 ranging from 0.1-10 mg/kg. The lowest dose, 0.01 mg/kg had no effect while 0.1 mg/kg produced a sub-maximal effect. The higher doses, 1 and 10 mg/kg produced equivalent effects. Similarly, the raclopride-induced paw drag in mice (as indicated by reduced numbers of steps), was reversed by 0.1-10 mg/kg CCG-203769 ( Figure   5B ).
In this report, we have characterized the first TDZD RGS inhibitor with physiological activity. CCG-203769, has nanomolar potency against RGS4 and RGS19 in vitro and is almost 5000-fold selective for RGS4 over the closely related RGS8, making CCG-203769 the most selective RGS4 inhibitor identified to date. As expected, cellular activity is less potent with halfmaximal effects occurring in the 1-3 µM range in cells. The inducible RGS4 system provided us with strong evidence of actions on RGS4 rather than other mechanisms that could also result in potentiation of the M3 muscarinic signaling response (e.g. M3 muscarinic allosteric modulation or effects on cellular Ca ++ handling). There are, however, additional actions of CCG-203769 at higher concentrations that are not fully understood.
Despite its cysteine-reactive mechanism of action, CCG-203769 selectively targets RGS4 over the known TDZD target GSK3β, the cysteine protease papain, and a large number of receptors and ion channels. The mechanism underlying the RGS selectivity of this compound over other cysteine-dependent processes has yet to be fully elucidated, however the available data allow for a potential explanation. We previously showed that the covalent modification of RGS4 was through opening of the thiadiazolidinone ring to form a disulfide bond with cysteine residues on the protein (25, 26) . This reactivity would presumably provide a non-specific mechanism of action. However, dynamic modeling studies (35) indicate that the target cysteines on RGS4 are buried in a hydrophobic environment that is only transiently accessible to solvent. This suggests that the cysteines in RGS4 may be in a unique environment that facilities the high potency of CCG-203769. Also, in the reducing environment of the cell, the disulfide-bonded compound interaction is likely reversible, as shown in vitro with addition of reducing agents (25) . Further studies are required to confirm these hypotheses.
In this report, we show that a TDZD RGS4 inhibitor, despite a covalent mechanism of action, is very selective for RGS4 over other RGS proteins as well over other sulfhydryldependent enzymes and a wide range of CNS receptors. Furthermore, it has in vivo activity on RGS4-dependent control of heart rate and produces beneficial effects in a D2 antagonistmediated akinesia and bradykinesia. In conjunction with the genetic evidence that RGS4 knockout mice have reduced defects after 6-hydroxy dopamine injury (15) , these results suggest (25) ; forskolin, morphine, and SNC80 (30) . Raclopride was purchased from Tocris Bioscience (Bristol, UK). CCG-203769 and CCG-50014 were synthesized as previously described (26) . Fluo4 NW kits were obtained from (InVitrogen, Carlsbad, CA). RGS proteins and Gα subunits were expressed, purified, and labelled as previously described (37) .
GSK-3β was obtained from Sigma (catalog #G1663). HEK-293T cells expressing the M3
muscarinic receptor and inducible RGS4 (M3-R4 cells) were described previously (38) . RGS/Gα binding studies: The binding of biotinylated RGS proteins to fluorescently labeled Gα o and the reversibility of RGS4 inhibitor compound actions were measured by Flow Cytometry
Protein Interaction Assay (FCPIA) as previously described (37, 39, 40) .
Single-turnover GAP assay: Single turnover GTPase acceleration experiments were performed as previously described using purified his 6 -tagged Gα o (25) .
Steady-state GAP assay: Steady-state hydrolysis of unlabeled GTP was measured using malachite green in a receptor-independent assay utilizing a mutant Gα i1 (R178M, A326S) (38, 41) .
These mutations facilitate the release of GDP from the enzyme making the GTP hydrolysis step rate-limiting (41) . GTP hydrolysis was measured by mixing 6 µM mutant Gα i with 300 µM GTP in 100 µL in 96-well plates in the presence or absence of 200 nM RGS4 and CCG-203769 or DMSO (vehicle control). All assay components were diluted in a buffer comprising 50 mM HEPES at pH 7.4, 100 mM NaCl, 0.01% Lubrol, 5 mM MgCl, and 10 µg/mL BSA. The reaction was allowed to proceed for 2 hours at room temperature and then was quenched with 60 µL of an HCl/malachite green dye solution. Immediately after addition of malachite green, 10 µL of 32% w/v sodium citrate was added as a colorimetric stabilizer, followed by incubation at room temperature for 20 minutes. Released inorganic phosphate was measured as an 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 increase in absorbance (A 630 ) from the complex of phosphate with malachite green (42) .
Background control samples lacking Gα were used to determine the rate of non-enzymatic GTP hydrolysis which was subtracted.
Papain inhibition: Experiments were performed using fluorescein-isothiocyante-labeled casein as the fluorescent substrate as previously described (25) .
GSK-3β inhibition: Purified GSK-3β (0.5 U, Sigma G1663) was incubated with the indicated concentration of compound for 15 minutes at room temperature. Substrate peptide (300 nM, Enzo #BML-P151) was added along with 1 mM [γ- Opioid inhibition of cellular cAMP: SH-SY5Y cells were grown in DMEM containing 10% fetal bovine serum and Penicillin (100 units/ml)-Streptomycin (100 µg/ml) under 5% CO 2 at 37°C.
Cells were plated into 24-well plates to reach ~ 90% confluency on the day of assay and washed once with fresh serum-free medium. Medium was replaced with 1 mM IBMX (3-isobutyl-1-methylxanthine) in serum-free medium for 15 minutes at 37°C, and then changed to medium containing 1 mM IBMX, 30 µM forskolin, and 100 nM of either morphine or SNC80 with or without test compound for 5 min at 37 °C. Reactions were stopped by replacing the medium with ice-cold 3% perchloric acid and samples were kept at 4 °C for at least 30
minutes. An aliquot (0.4 ml) from each sample was removed, neutralized with 0.08 ml of 2.5 M KHCO 3 , vortexed, and centrifuged at 15,000 x g for 1 minute to pellet the precipitates.
Accumulated cAMP in a 10-15 µl aliquot of the supernatant from each sample was measured Calcium signaling transients: The M3-R4 cell line with regulated expression of RGS4 (38) RGS4 membrane localization: Assays were performed as previously described (25) . Briefly, HEK-293T were cells grown to 80-90% confluency in 6-well dishes in DMEM supplemented with 10% fetal bovine serum and Penicillin (100 units/ml)-Streptomycin (100 µg/ml) under 5% 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 to the abdominal wall. The catheter extending from the base of the transmitter was placed 3 cm into the left femoral artery. Electrodes from the bottom of the transmitter were threaded subcutaneously and one was sutured to the muscle above the xiphoid process and the other was sutured to the right of the clavicle. All rats were singly housed and allowed at least 7 days to recover before testing.
The telemetry system consisted of battery-operated transmitters and receivers (Data 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 light/dark cycle with lights on between 07:00 and 19:00. Prior to pharmacological testing, mice were handled for 1 week by the same operator to reduce stress, and trained daily for a week on the behavioral tests until their motor performance became reproducible. On the day of experiment drugs were administered systemically (i.p.); CCG-203769 was administered 30 min after raclopride.
Motor activity was evaluated by means of different behavioral tests (bar and drag) specific for different motor abilities, as previously described (43, 44) . The bar test or catalepsy test (45) , measures the ability of the animal to respond to an externally imposed static posture. Each mouse was placed gently on a table and the right and left forepaws were placed alternately on blocks of increasing heights (1.5, 3 and 6 cm). The immobility time (in seconds) on the blocks was recorded (cut-off time 20 seconds per step, 60 seconds maximum). Time was recorded as total time spent on the blocks. The drag test is a modification of the "wheelbarrow" test (46) . Each mouse was gently lifted by the tail (allowing the forepaws on the table) and dragged backwards at a constant speed (about 20 cm/sec) for a fixed distance (100 cm). The number of touches made by each forepaw was counted by two separate observers (mean between the two forepaws). Data are expressed as means ± SEM of n determinations per group. Statistical analysis was performed using one-way repeated measures (RM) ANOVA followed by the NewmanKeuls test. P values <0.05 were considered to be statistically significant. Both raclopride and CCG-203769 were freshly dissolved in the vehicle just prior to use. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Page 18 of 33
ACS Paragon Plus Environment
ACS Chemical Neuroscience
